Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.
Guardia C, Bianchini G, Arpí-LLucià O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero JC, Soria-Jiménez L, Sabbaghi M, Peña R, Madoz-Gúrpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Guardia C, et al. Among authors: casadevall d. Clin Cancer Res. 2021 Sep 15;27(18):5096-5108. doi: 10.1158/1078-0432.CCR-20-2915. Epub 2021 Aug 12. Clin Cancer Res. 2021. PMID: 34385295
Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC.
Rocha P, Ramal D, Ripoll E, Moliner L, Corbera A, Hardy-Werbin M, Orrillo M, Taus Á, Zuccarino F, Gibert J, Perera-Bel J, Casadevall D, Arriola E. Rocha P, et al. Among authors: casadevall d. JTO Clin Res Rep. 2020 Oct 28;2(1):100115. doi: 10.1016/j.jtocrr.2020.100115. eCollection 2021 Jan. JTO Clin Res Rep. 2020. PMID: 34589976 Free PMC article.
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.
Pérez-Núñez I, Rozalén C, Palomeque JÁ, Sangrador I, Dalmau M, Comerma L, Hernández-Prat A, Casadevall D, Menendez S, Liu DD, Shen M, Berenguer J, Ruiz IR, Peña R, Montañés JC, Albà MM, Bonnin S, Ponomarenko J, Gomis RR, Cejalvo JM, Servitja S, Marzese DM, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celià-Terrassa T. Pérez-Núñez I, et al. Among authors: casadevall d. Nat Cancer. 2022 Mar;3(3):355-370. doi: 10.1038/s43018-022-00339-4. Epub 2022 Mar 17. Nat Cancer. 2022. PMID: 35301507
Characterization and spatial distribution of the immune cell infiltrate in triple-negative breast cancer: a novel classification based on plasma cells and CD8+ T cells.
Gonzàlez-Farré M, Gibert J, Santiago-Díaz P, Menéndez S, Monzonis X, Olivares F, Riera X, López D, Torner A, Casado B, Bellosillo B, Lloveras B, Casadevall D, Rovira A, Servitja S, Albanell J, Vázquez I, Comerma L. Gonzàlez-Farré M, et al. Among authors: casadevall d. Hum Pathol. 2023 Sep;139:91-105. doi: 10.1016/j.humpath.2023.07.010. Epub 2023 Jul 28. Hum Pathol. 2023. PMID: 37517596
Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial.
Vidal J, Casadevall D, Bellosillo B, Pericay C, Garcia-Carbonero R, Losa F, Layos L, Alonso V, Capdevila J, Gallego J, Vera R, Salud A, Martin-Richard M, Nogué M, Cillán E, Maurel J, Faull I, Raymond V, Fernández-Martos C, Montagut C. Vidal J, et al. Among authors: casadevall d. Clin Cancer Res. 2021 May 15;27(10):2890-2898. doi: 10.1158/1078-0432.CCR-20-4769. Epub 2021 Mar 16. Clin Cancer Res. 2021. PMID: 33727257 Clinical Trial.
Comprehensive Analysis of Metabolic Isozyme Targets in Cancer.
Marczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, Shan NL, Blenman KRM, O'Meara TA, Umlauf S, Surovtseva YV, Muthusamy V, Rinehart J, Perry RJ, Kibbey R, Hatzis C, Pusztai L. Marczyk M, et al. Among authors: casadevall d. Cancer Res. 2022 May 3;82(9):1698-1711. doi: 10.1158/0008-5472.CAN-21-3983. Cancer Res. 2022. PMID: 35247885 Free PMC article.
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.
Vidal J, Fernández-Rodríguez MC, Casadevall D, García-Alfonso P, Páez D, Guix M, Alonso V, Cano MT, Santos C, Durán G, Elez E, Manzano JL, Garcia-Carbonero R, Ferreiro R, Losa F, Pineda E, Sastre J, Rivera F, Bellosillo B, Tabernero J, Aranda E, Salazar R, Montagut C; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Vidal J, et al. Among authors: casadevall d. Clin Cancer Res. 2023 Jan 17;29(2):379-388. doi: 10.1158/1078-0432.CCR-22-1696. Clin Cancer Res. 2023. PMID: 36074154
28 results